Tharimmune (THAR) Stock Analysis

What Tharimmune does

Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid tumors; and TH1940, specifically targeting programmed cell death protein 1 (PD-1). Furthermore, the company has entered into a research collaboration and product license agreement with Minotaur Therapeutics, Inc. to develop proprietary targeted biologics. Originally incorporated in 2017 as Hillstream BioPharma, Inc., the company rebranded to Tharimmune, Inc. in September 2023 and maintains its headquarters in Bridgewater, New Jersey.

Key metrics

ETFs linked to THAR

Broad-market and Healthcare sector ETFs an investor holding Tharimmune is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how THAR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Tharimmune?

Tharimmune trades under the ticker THAR on NASDAQ.

Which exchange is THAR listed on?

THAR is listed on NASDAQ.

What sector does Tharimmune operate in?

Tharimmune is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze THAR in a portfolio?

PortView shows THAR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.